ATOS Atossa Therapeutics Inc

Price (delayed)

$4.77

Market cap

$41.08M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.55

Enterprise value

$9.25M

?
Relative Growth: Rel. Growth: 2
Relative Strength: Rel. Strength: 7
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 2

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and ...

Highlights
The quick ratio has dropped by 64% year-on-year and by 15% since the previous quarter
The company's equity has shrunk by 53% YoY and by 23% QoQ

Key stats

What are the main financial stats of ATOS

ATOS stock price

How has the Atossa Therapeutics stock price performed over time
Intraday
1.49%
1 week
-8.09%
1 month
-18.6%
1 year
-62.91%
YTD
-46.1%
QTD
-9.32%

Financial performance

How have Atossa Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$39.6M
Net income
-$37.64M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 43% YoY and by 8% from the previous quarter
The operating income fell by 41% YoY and by 7% QoQ

Price vs fundamentals

How does ATOS's price correlate with its fundamentals

Growth

What is Atossa Therapeutics's growth rate over time

Valuation

What is Atossa Therapeutics stock price valuation
P/E
N/A
P/B
1.35
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 41% YoY and by 13% QoQ
The company's equity has shrunk by 53% YoY and by 23% QoQ
ATOS's P/B is 30% below its last 4 quarters average of 1.9 and 26% below its 5-year quarterly average of 1.8

Efficiency

How efficient is Atossa Therapeutics business performance
The return on equity has dropped by 134% year-on-year and by 29% since the previous quarter
The ROA has plunged by 115% YoY and by 25% from the previous quarter

Dividends

What is ATOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ATOS.

Financial health

How did Atossa Therapeutics financials performed over time
The quick ratio has dropped by 64% year-on-year and by 15% since the previous quarter
Atossa Therapeutics's current ratio has plunged by 61% YoY and by 11% from the previous quarter
ATOS's debt is 100% smaller than its equity
The company's equity has shrunk by 53% YoY and by 23% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.